Rui Ferreira graduated in Biology in July 2006 at the University of Aveiro. During graduation, he did a training programme at Centre for Protein Engineering, University of Liège, through the Leonardo Da Vinci programme (European Commission) to study a novel extended spectrum β-lactamase (TEM-121) from Enterobacter aerogenes. In the same year he joined the Cancer Genetics research group at Ipatimup to investigate the role of Helicobacter pylori virulence factors in the development of gastric cancer using in vitro models and clinical specimens. During his PhD, he visit to the laboratory of Professor Dulciene Queiroz from UFMG (Belo Horizonte, Brazil) to develop technical skills to isolate H. pylori strains from gastric clinical specimens. At the end of 2012, he got his PhD from the Faculty of Medicine of the University of Porto in frame of the Doctoral Programme in Biomedicine. In 2013, I was awarded with an individual post-doctoral fellowship from FCT to investigate the role of H. pylori and the gastric microbiome in gastric cancer. Since then, he was responsible for the implementation of an animal model of gastric carcinogenesis at i3S. He has also been implementing state-of-the-art pipelines to analyse next-generation sequencing microbiome data. Currently, he holds an Assistant research position awarded in a highly competitive individual call promoted by FCT (Scientific Employment Stimulus – 2017). Importantly, my recent scientific production led to filling of a patent application on microbiome markers for gastric cancer and to the publication in a top journal in the area of Gastroenterology (Gut, IF: 17.943, Q1). As a result of his scientific activities, he has published 40 papers in international peer-reviewed journals, of which he is first author in 12 papers (h-index of 18). He is also author of 2 book chapters. Altogether, his research efforts produced solid data, based on which the Worldwide Cancer Research, FCT, and the Horizon 2020 research and innovation programme have funded the research of the Group in last years. Recently, he is leading an FCT funded project aiming to identify microbiome metabolites as biomarkers in gastrointestinal cancers.